Dizocilpine derivatives as peripheral NMDA receptor antagonists

1. Compound of formula (I):

wherein:

R 1 represents a cyclopropyl group;

R 2 represents a (C 1 -C 10 )alkyl group;

n is 1;

R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and R 10 represent a hydrogen atom; and X − is an anionic counterion selected from the group consisting of I − , Cl − , Br − and OH −.

2. Compound according to claim 1 , wherein R 2 represents a methyl group or an ethyl group.

3. Compound according to claim 1 , wherein the anionic counterion X − is selected from the group consisting of I − and Cl −.

4. A pharmaceutical composition comprising at least one compound according to claim 1 , and at least one pharmaceutically acceptable excipient.

5. A method for A method for treating a disease or condition in a subject comprising administering to the subject a compound according to claim 1 , wherein the disease or the condition is pulmonary hypertension.

6. A method for treating a disease or condition in a subject comprising administering to the subject a compound according to the claim 1 , wherein the disease or the condition is selected from the group consisting of pulmonary arterial hypertension and thromboembolic pulmonary hypertension.

7. A method for treating a disease in a subject comprising administering to the subject a compound according to claim 1 , wherein the disease is pulmonary arterial hypertension.

8. Compound according to claim 1 , chosen from:

9. Compound according to claim 1 , wherein R 2 represents a methyl group.

10. Compound according to claim 1 , wherein R 2 represents an ethyl group.

11. Compound according to claim 1 , wherein X − is I −.

12. Compound according to claim 1 , wherein X − is Cl −.

13. Compound according to claim 1 , wherein X − is Br −.

14. Compound according to claim 1 , wherein X − is OH −.